Oramed Pharmaceuticals Inc.
ORMP Healthcare Biotechnology
In the quarter to June 2026, revenue grew 193.3%, EPS grew 493.8% and free cash flow grew 94.3%, each against the same quarter a year earlier.
Follow ORMP
Oramed Pharmaceuticals Inc. (ORMP) Altman Z-score
Oramed Pharmaceuticals Inc.'s Altman Z-score for fiscal 2025 is 1.91, in the grey zone (1.81–2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 1.91 | 1.58 |
| FY2023 | 0.33 | (25.41) |
| FY2022 | 25.74 | 8.57 |
| FY2022 | 17.17 | (10.92) |
| FY2021 | 28.10 | (0.15) |
| FY2021 | 28.25 | 27.34 |
| FY2020 | 0.91 | 2.26 |
| FY2019 | −1.34 | (1.79) |
| FY2018 | 0.45 | (0.67) |
| FY2017 | 1.12 | (0.68) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.49 | — | 0.59 | |
| Retained earnings / total assets | (0.53) | — | −0.75 | |
| EBIT / total assets | (0.07) | — | −0.22 | |
| Market value of equity / total liabilities | 3.79 | — | 2.28 | |
| Sales / total assets | 0.01 | — | 0.01 | |
| Altman Z-score | Grey zone | 1.91 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 7.80 | ||
Z and Z″ put Oramed Pharmaceuticals Inc. in different zones: grey zone by Z, safe zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ACOG Alpha Cognition Inc. compare | 2.5× |
| ORMP Oramed Pharmaceuticals Inc. | 1.9× |
| WHWK Whitehawk Therapeutics, Inc. compare | 1.5× |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | 1.0× |
| DTIL Precision BioSciences, Inc. compare | −4.3× |
| CHRS Coherus Oncology, Inc. compare | −8.8× |
| IPHA Innate Pharma S.A. Sponsored ADR compare | −11.2× |
| ELDN Eledon Pharmaceuticals, Inc. compare | — |
| PEPG PepGen, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets